10-Q: MaxCyte Reports Third Quarter 2024 Results, Revenue Up 17% Year-Over-Year

MaxCyte's third quarter results show a 17% increase in revenue year-over-year, driven by disposables and program-related revenue, while the company continues to invest in growth and development.

Summary

• MaxCyte reported a net loss of $30.5 million for the nine months ended September 30, 2024, with an accumulated deficit of $206.3 million.
• Total revenue for the nine months ended September 30, 2024, was $29.9 million, a 17% increase compared to $25.6 million in the same period of 2023.
• Core revenue increased by 5% to $23.9 million, driven by a 21% increase in disposables revenue, while instrument revenue decreased by 9%.
• Program-related revenue saw a significant increase of 104%, reaching $6.0 million for the nine months ended September 30, 2024.
• Gross profit for the nine months ended September 30, 2024, was $25.1 million, with a gross margin of 84%, compared to 88% in the same period of 2023.
• Operating expenses totaled $63.4 million for the nine months ended September 30, 2024, with research and development expenses decreasing slightly by 2%.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While revenue growth is positive, the decrease in gross margin and continued net losses temper the overall sentiment. The company's strategic partnerships and growth in disposables revenue are encouraging, but the potential risks and challenges need to be considered.

Positives

• The company experienced a substantial increase in program-related revenue, indicating successful progress of partner programs.
• Disposables revenue showed strong growth, suggesting increased utilization of MaxCyte's technology by existing customers.
• The company continues to expand its customer base by securing new SPL agreements.
• Overall revenue increased by 17% year-over-year, demonstrating positive business momentum.

Negatives

• The company reported a net loss of $30.5 million for the nine months ended September 30, 2024.
• Gross margin decreased to 84% for the nine months ended September 30, 2024, compared to 88% in the same period of 2023.
• Instrument revenue decreased by 9% for the nine months ended September 30, 2024.
• The company has an accumulated deficit of $206.3 million.

Risks

• The company is currently evaluating the benefits and challenges of maintaining dual listings on both AIM and Nasdaq, and may consider concentrating trading on Nasdaq, which could affect share liquidity and price.
• The company's revenue may fluctuate due to the timing of product sales and licenses, the uncertain nature of partner clinical progress, and dependence on partner program decisions.
• The company is subject to market risk for changes in interest rates and foreign currency exchange rates.
• The company has incurred significant operating losses since inception and expects to continue to incur net losses as it invests in growth.

Future Outlook

The company expects total revenue to increase over time as customer programs advance and markets grow, resulting in additional instrument sales, leases, and disposable sales. They also anticipate that revenue from cell therapy customers will continue to grow as those customers advance their preclinical pipeline programs into clinical development and move their existing drug development programs into later-stage clinical trials and, potentially, into commercialization. The company expects to continue to incur net losses as they focus on growing commercial sales, scaling manufacturing, and continuing research and development.

Management Comments

• The company believes that its continued investment in research and development is essential to its long-term competitive position.
• The company expects its recurring sales and marketing expenses to increase in absolute dollars in future periods as it expands its commercial sales, marketing and business development teams.
• The company expects that its general and administrative expenses will continue to increase in absolute dollars in future periods, primarily due to increased headcount to support anticipated growth in the business.

Industry Context

MaxCyte operates in the rapidly expanding cell therapy market, providing enabling platform technologies for the discovery, development, and commercialization of next-generation cell therapeutics. The company's technology is used by biopharmaceutical companies for cell engineering, including gene editing and immuno-oncology. The company is well-positioned to benefit from the growth in the cell therapy pipeline and the shift towards non-viral delivery approaches.

Comparison to Industry Standards

• MaxCyte's revenue growth of 17% year-over-year is a positive indicator in the competitive cell therapy market, although specific comparisons to peers are not provided in the document.
• The company's gross margin of 84% is relatively high, reflecting the premium pricing of its technology, but it is lower than the 88% reported in the same period of 2023.
• The company's continued investment in research and development is consistent with industry trends, as innovation is crucial for maintaining a competitive edge.
• The company's reliance on a limited number of suppliers and customers is a common risk in the biotech industry, and the company is actively managing this risk.
• The company's focus on strategic platform licenses (SPLs) is a common strategy in the biotech industry to generate recurring revenue and build long-term partnerships.

Related Party Transactions

• The company entered into a consulting agreement with a member of the Board of Directors for a 12-month period for an amount not to exceed $150.
• The company sold $84 in products to a customer whose Chief Executive Officer is a member of the company's Board of Directors.
• The company sold less than $1 in products to a customer whose Board of Directors includes a member who also serves on the company's Board of Directors.

Stakeholder Impact

• Shareholders may be concerned about the continued net losses and the potential impact of a change in stock exchange listings.
• Employees may be impacted by the company's growth and expansion plans.
• Customers will benefit from the company's continued investment in research and development and product enhancements.
• Suppliers may see increased business as the company scales its manufacturing operations.

Next Steps

• The company will continue to focus on growing commercial sales of its products in both the U.S. and international markets.
• The company will continue to scale its manufacturing operations.
• The company will continue research and development efforts to develop new products and further enhance existing products.
• The company is evaluating the benefits and challenges of maintaining dual listings on both AIM and Nasdaq and may consider concentrating trading on Nasdaq.

Key Dates

Keywords

cell therapy, electroporation, biopharmaceutical, revenue, strategic platform license, disposables, gross margin, research and development, financial results, SPL